Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
26.09. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
22.09. | Summers Value Partners' Update on Journey Medical (DERM) | 5 | Insider Monkey | ||
28.08. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
25.08. | H.C. Wainwright stuft Journey Medical mit "Kaufen" ein - Rosacea-Medikament Emrosi als entscheidender Faktor | 9 | Investing.com Deutsch | ||
25.08. | H.C. Wainwright initiates Journey Medical stock with Buy rating on Emrosi potential | 2 | Investing.com | ||
20.08. | Journey Medical setzt auf Rosacea-Mittel Imrozi für Profitabilitätswende | 5 | Investing.com Deutsch | ||
13.08. | Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples | 4 | Seeking Alpha | ||
12.08. | Journey Medical Corp - 10-Q, Quarterly Report | 4 | SEC Filings | ||
12.08. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
12.08. | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 522 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen | |
11.08. | Examining the Future: Journey Medical's Earnings Outlook | 2 | Benzinga.com | ||
07.08. | Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 | 3 | GlobeNewswire (USA) | ||
05.08. | Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 | 1 | GlobeNewswire (USA) | ||
14.07. | Journey Medical Corp - 8-K, Current Report | 3 | SEC Filings | ||
14.07. | Journey Medical's rosacea treatment reaches 65% commercial coverage | 2 | Investing.com | ||
14.07. | Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi | 2 | GlobeNewswire (USA) | ||
24.06. | Journey Medical to join Russell 2000 and 3000 indexes | 3 | Investing.com | ||
24.06. | Journey Medical Corporation: Journey Medical to Join Russell 2000 and Russell 3000 Indexes | 1 | GlobeNewswire (USA) | ||
24.06. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
20.06. | Journey Medicals Rosacea-Medikament zeigt Wirksamkeit unabhängig vom Gewicht | 1 | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 23,145 | +0,11 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Die Studiendaten des GLP-1-Abnehmmittels MET-097i Metsera... ► Artikel lesen | |
GILEAD SCIENCES | 93,97 | -0,39 % | Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences | HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supplyHONG KONG, Sept. 29, 2025 /PRNewswire/ -- Health Hope Pharma Limited ("HHP") today announced... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 348,20 | -0,17 % | Vertex Pharmaceuticals: Zwischen Höhenflug und Gegenwind | Vertex Pharmaceuticals ist seit Jahren vor allem durch seine Führungsrolle in der Behandlung von Mukoviszidose bekannt. Doch während die Forschung große Fortschritte zeigt, gerät die Aktie nach außergewöhnlich... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 10,815 | -6,12 % | EyePoint stock rating reiterated at Outperform by Mizuho amid competitor review | ||
ROCKET LAB | 44,400 | -0,89 % | Wochenrückblick 39/2025: Meine stärksten Kurstreiber im Depot waren Almonty, KKR, AeroVironment, Viper Energy, LendingClub. Aber (noch) mehr Action gab' bei Funkwerk, Rocket Lab - und Costco... | Die Top-Werte meines Investmentdepots veröffentliche ich jeweils zum Quartalsende in meinen Investor-Updates und meine Beobachtungsliste aktualisiere ich wöchentlich.Ergänzend gebe ich heute eine kurze... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 6,350 | -3,79 % | Astria Therapeutics, Inc.: Astria Therapeutics rekrutiert nun HAE-Patienten in der Europäischen Union für die Phase-3-Studie ALPHA-ORBIT | Astria Therapeutics, Inc. (Nasdaq:ATXS), ein Biopharma-Unternehmen mit Schwerpunkt auf der Entwicklung lebensverändernder Therapien für allergische und immunologische Erkrankungen, gab heute bekannt... ► Artikel lesen | |
OPKO HEALTH | 1,300 | -0,75 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
LIGAND PHARMACEUTICALS | 155,00 | +0,65 % | Ligand Pharmaceuticals: Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance | Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million)... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 115,90 | -1,02 % | Jazz Pharma: FDA Approves Zepzelca + Tecentriq Combo For First-Line Maintenance In ES-SCLC Patients | WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) announced that it has received U.S. FDA approval for Zepzelca (lurbinectedin) in combination with either atezolizumab (Tecentriq) or atezolizumab... ► Artikel lesen | |
UNITED THERAPEUTICS | 377,60 | -0,24 % | TD Cowen bestätigt Kaufempfehlung für United Therapeutics und verweist auf IPF-Potenzial | ||
ROYALTY PHARMA | 31,260 | +0,39 % | Goldman Sachs initiates Royalty Pharma stock with Buy rating, $42 target | ||
CATALYST PHARMACEUTICALS | 17,670 | -0,67 % | CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report | ||
BRIDGEBIO PHARMA | 45,240 | -0,48 % | BridgeBio Pharma, Inc.: Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM | - By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo- Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus... ► Artikel lesen | |
TG THERAPEUTICS | 30,980 | -0,97 % | TG Therapeutics, Inc.: New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment | During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI... ► Artikel lesen | |
AVADEL PHARMACEUTICALS | 12,600 | -1,56 % | Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding | A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation)... ► Artikel lesen |